BIO-TECHNE Corp
BIO-TECHNE Corp (TECH): 10 pipeline candidates · 3 upcoming catalysts · ~8 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
8.0 months
1% dilution
Lead: Approved
10 candidates
3 upcoming, next in ~190d
0 buys · 2 sells (180d)
A transparent, data-derived signal for BIO-TECHNE Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.6B
Cash
$209.8M
Quarterly Burn
$132.8M
Runway
8.0 mo
Revenue
$311.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
580
Total value held
$9.37B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 20,359,418 | $1.06B |
| blackrock, inc. | 12,264,513 | $640.9M |
| morgan stanley | 8,532,873 | $445.9M |
| fmr llc | 7,899,928 | $412.9M |
| vanguard portfolio management llc | 6,480,337 | $338.7M |
| state street corp | 5,868,396 | $306.7M |
| wellington management group llp | 5,120,185 | $267.6M |
| geode capital management, llc | 5,112,420 | $266.8M |
| maverick capital ltd | 4,739,721 | $247.7M |
| durable capital partners lp | 4,456,017 | $232.9M |
Showing top 10 of 580 institutional holders of BIO-TECHNE Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BIO-TECHNE Corp's pipeline?
BIO-TECHNE Corp (TECH) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIO-TECHNE Corp's next catalyst?
BIO-TECHNE Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of" — expected December 25, 2026.
What is BIO-TECHNE Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIO-TECHNE Corp has approximately 8.0 months of cash runway.
What is BIO-TECHNE Corp's market capitalization?
BIO-TECHNE Corp's market capitalization is approximately $8.6B.
Who is the CEO of BIO-TECHNE Corp?
Mr. Kim Kelderman is the chief executive officer of BIO-TECHNE Corp (TECH).
Get the full picture on BIO-TECHNE Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.